Research is being conducted on the combination of SGLT2 inhibitors and GLP-1 receptor agonists for patients with type 2 diabetes mellitus, with some studies suggesting this combination may provide greater benefits than monotherapy. The combination is being examined for its effects on cardiovascular and renal outcomes, as well as its comparative efficacy and safety. The potential benefits and future clinical perspectives of this combination therapy are being explored in various analyses and studies.